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Abstract
Background and objective Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with 
hemophilia A. FVIII product stability under high and fluctuating temperatures is important, particularly for patients who 
reside in, or travel to, regions with high ambient temperatures, as they may remove their product from the refrigerator and 
return it, unused, multiple times. We evaluated the effect of variable temperature storage conditions, including up to 40 °C, 
on the stability of the recombinant FVIII product, turoctocog alfa.
Methods Turoctocog alfa dry powder stability was assessed when moved between storage conditions of 5 °C (ambient 
humidity) and 40 °C (75% relative humidity) multiple times over a 2-month period, followed by long-term storage at 40 °C 
for 3 months and 5 °C for 1 month. Three product strengths (250, 1500, and 3000 IU), including the lowest and highest doses, 
were evaluated. Stability assessments included potency, purity, oxidized forms, high molecular weight protein (HMWP), 
and water content.
Results Overall, the three doses of turoctocog alfa tested remained stable under varying temperature conditions, without 
any potency or purity impairment, nor were any major increases in oxidized forms, HMWP, or water content observed. All 
results were within shelf-life specification limits.
Conclusion The results demonstrated that turoctocog alfa can be subjected to variable storage conditions, including cycling 
between 5 °C and ≤ 40 °C, and subsequent storage for 3 months up to 40 °C, without loss of stability. This suggests that turoc-
tocog alfa may offer greater product storage flexibility for patients in everyday practice, with a potential reduction in wastage.
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Key Points 
Patient survey results indicate it is important that factor 
VIII products are stable at various temperatures.
Stability of the recombinant factor VIII, turoctocog alfa, 
was assessed after cycling between 5 °C and ≤ 40 °C, 
and after 3 months at ≤ 40 °C (conditions simulating 
those experienced in everyday life).
For all doses tested, stability parameters such as potency 
and purity were not impaired.
1 Introduction
Factor VIII (FVIII) is indicated to treat bleeding episodes or 
prevent bleeding in patients with hemophilia A [1]. It is usu-
ally administered at home by the patient or their caregiver, 
enabling direct access to therapy. This results in greater free-
dom for the patient and facilitates early treatment, which has 
been shown to improve clinical outcomes [1, 2].
The stability of FVIII products under varying tempera-
ture conditions has been reported as an important element 
of patient satisfaction, as it allows patients more freedom 
in their daily lives, particularly with regard to sports and 
traveling to countries with high daytime temperatures [3, 
4]. As such, an important aspect of any FVIII replacement 
product is its storage flexibility [3]. A survey of patients 
with hemophilia and/or their caregivers revealed that 47.4% 
had discarded unused product and, in 26.6% of cases, this 
was due to storage problems [5]. As many patients and/or 
their caregivers experience financial difficulties related to the 
cost of clotting factor products [6], any reduction in product 
waste is desirable.
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Published studies on the stability of FVIII products at 
very high temperatures are scarce [7, 8] and, to our knowl-
edge, only one has investigated product stability in response 
to multiple sequences of temperature cycling; that study 
demonstrated the stability of octocog alpha when cycled 
three times through room temperature and refrigerated stor-
age [9]. Temperature cycling is an important parameter to 
assess, as it simulates a situation in which the product is 
removed from the refrigerator and then returned, unused, 
multiple times—a normal activity for many patients. For 
example, patients who carry their FVIII product with them 
when conducting daily activities or participating in physical 
activity may not experience a bleed for some time, which can 
result in the product being subjected to varying temperature 
conditions. Additionally, when patients are traveling, the 
FVIII product may be exposed to unpredictable changes in 
temperature and humidity, especially if traveling to a hot 
country and moving between air-conditioned environments. 
Furthermore, a disruption of the cold chain during product 
distribution could occur in some regions, resulting in tem-
perature cycling between refrigerated storage and ambient 
conditions [10, 11].
Turoctocog alfa  (NovoEight®, Novo Nordisk, Bagsværd, 
Denmark) is a recombinant FVIII product for the prophy-
laxis and treatment of bleeding, and for coverage during 
surgery in patients with hemophilia A [12–14]. Turoctocog 
alfa is supplied as dry powder in single-dose vials of 250, 
500, 1000, 1500, 2000, and 3000 IU. The dry powder can 
be stored at ≤ 40 °C for up to 3 months and the reconstituted 
product at ≤ 40 °C for up to 4 h [15, 16].
The aim of this study was to assess the stability of turoc-
tocog alfa dry powder when moved between storage con-
ditions of 5 °C and 40 °C multiple times over a 2-month 
period, followed by long-term storage at 40 °C for 3 months 
and then at 5 °C for 1 month.
2  Methods
2.1  Recombinant Factor VIII Product and Sample 
Preparation
This study used commercially available turoctocog alfa dry 
powder batches representing the lowest, middle, and high-
est strengths of the drug product (250, 1500, and 3000 IU).
2.2  Study Design
The stability of turoctocog alfa dry powder batches under 
varying storage conditions was investigated over the 
full 30-month shelf-life period [15, 16], with sampling 
throughout the study period (see below for further details) 
(Fig. 1). All drug products were initially stored at 5 °C for 
24 months to enable testing toward the end of the product’s 
shelf-life. Turoctocog alfa test samples were then cycled 
ten times between 5 °C with ambient humidity (AH) and 
40 °C with 75% relative humidity (RH) over a period of 
2 months. One cycle was equal to 96 h at 5 °C and 72 ± 2 h 
at 40 °C. After 10 temperature cycles, test samples were 
stored at 40 °C/75% RH for 3 months and then at 5 °C/AH 
for 1 month (the 1-month period at 5 °C allowed the full 
30-month shelf-life to be reached). Reference samples were 
stored at 5 °C, whereas test samples underwent temperature 
cycling and were then stored at 40 °C/75% RH for 3 months 
and at 5 °C/AH for 1 month, alongside the test samples. 
For the test samples, purity, high molecular weight proteins 
(HMWPs), and oxidized forms were assessed after each 
temperature cycle, once a month during storage at 40 °C 
(3 months), and at study end (after 1 month at 5 °C). Potency 
and water content were assessed after temperature cycles 
1, 3, 5, 7, 9, and 10, once a month during storage at 40 °C, 
and at study end (after 1 month at 5 °C). Reference samples 
Fig. 1  Study design. The stability of turoctocog alfa dry product was 
assessed following temperature cycling (ten times between 5 °C and 
40 °C), and after storage at 40 °C for 3 months and 5 °C for 1 month. 
*One cycle is equal to 96 h at 5 °C and 72 ± 2 h at 40 °C. AH ambient 
humidity, RH relative humidity
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were assessed at day 31 (equivalent to cycle 5) and day 66 
(equivalent to cycle 10), once a month during storage at 
40 °C (3 months), and at study end (after 1 month at 5 °C).
2.3  Assay Methods
The study was performed according to current International 
Conference for Harmonisation bracketing design guidelines 
[17]. The parameters assessed include those from the drug 
product specification that are susceptible to change during 
storage and/or those likely to influence product quality. The 
results from all assays were compared with turoctocog alfa 
250-, 1500-, and 3000-IU reference samples and evaluated 
against predetermined specification limits, calculated using 
appropriate statistical methods [17]. The specific limits 
for each assay are noted within the appropriate following 
sections.
2.3.1  Potency
Potency was investigated using the chromogenic kit 
 Coamatic® FVIII (Chromogenix, Instrumentation Labora-
tory, Bedford, MA, USA) on the  ACL® Elite Pro analyzer 
(Instrumentation Laboratory) in accordance with European 
Pharmacopoeia Assay of human coagulation FVIII using 
a product-specific standard as calibrator. Turoctocog alfa 
product samples and the product-specific calibrator were 
reconstituted in 4.3 ml 0.9% sodium chloride before under-
going three dilution steps: (1) predilution to approximately 
11 IU/ml using the  Coamatic® FVIII kit buffer solution; 
(2) dilution to approximately 1 IU/ml using FVIII-deficient 
plasma; (3) dilution to approximately 0.005 IU/ml using the 
 Coamatic® FVIII kit buffer solution. Blank samples were 
prepared by dilution of 20-µl FVIII-deficient plasma with 
4000-µl buffer solution.
Turoctocog alfa product samples, calibrator, and blank 
samples were analyzed in triplicate on the  ACL® Elite Pro 
analyzer. Absorbance readings for product and reference 
samples and calibrator were used to calculate the potency 
(FVIII:C) using a slope-ratio analysis. The acceptance crite-
ria for the potency of the three turoctocog alfa samples were 
defined as follows: 200–313 IU/vial for the 250-IU dose; 
1200–1875 IU/vial for the 1500-IU dose; 2400–3750 IU/
vial for the 3000-IU dose.
2.3.2  Purity
The purity of reconstituted turoctocog alfa product samples 
was assessed using reverse-phase high-performance liquid 
chromatography (RP-HPLC). Analysis was performed on 
an HPLC system equipped with processing software and 
a 4.0 × 250-mm,  C4 5-μM, 300 Å column (Novo Nordisk 
Pharmatech A/S, Køge, Denmark). The column temperature 
was set at 40 °C, with a detection wavelength of 215 nm. 
A gradient of 35–100% eluent B (0.09% trifluoracetic acid 
[TFA] in 80% acetonitrile in purified water) and 65–0% 
eluent A (0.1% TFA in purified water) was applied over 
a duration of 40 min at a flow rate of 1 ml/min. The com-
position of 100% eluent B was then maintained for 5 min 
before the composition was changed back to the initial con-
ditions over 1 min and the column was then equilibrated 
for 14 min, resulting in a total run time of 60 min. The 
purity of the turoctocog alfa product was calculated as the 
sum of area percentages of the following components on 
the resulting chromatograms: turoctocog alfa light chain; 
turoctocog alfa single chain; and three heavy chain (HC) 
components (nontruncated form, one with the C-terminal 
at amino acid 740 [HC_740], and one with the C-terminal 
at amino acid 720 [HC_720]). The acceptance criterion 
was ≥ 89.4% purity.
2.3.3  Oxidized Forms
Oxidized forms within the reconstituted turoctocog alfa 
product were assessed using RP-HPLC. The RP-HPLC 
system, column, HPLC parameters (column temperature, 
detection wavelength, mobile phase eluents), and elution 
gradients used to assess oxidized forms were the same as 
those used to assess product purity. Oxidized forms were 
calculated as the percentage area on the resulting chromato-
grams. The acceptance criterion was ≤ 6.8% oxidized forms.
2.3.4  High Molecular Weight Proteins
Turoctocog alfa samples were analyzed by size exclusion-
HPLC (SE-HPLC) to determine the presence of protein 
aggregates. Prior to SE-HPLC analysis, product sam-
ples were reconstituted in either 1.0 (250-IU samples) or 
4.3 ml (1500- and 3000-IU samples) 0.9% sodium chloride 
solution. SE-HPLC measurements were performed using 
an HPLC system equipped with a BioSep SEC S3000 
7.8 × 300-mm, 5-μm, 290 Å column (Phenomenex, Tor-
rance, CA, USA) or a Shodex PROTEIN KW-803, 8 × 300-
mm column (Shodex) or equivalent. Elution was employed 
at a flow rate of 0.4 ml/min, using a column temperature of 
30 °C and excitation and emission detection wavelengths 
of 285 and 335 nm, respectively. The eluent buffer con-
sisted of 10 mM TRIS, 10 mM  CaCl2, 300 mM sodium 
chloride, and 5% 2-propanol pH 7.0; the injection volume 
of turoctocog alfa was 100 µl, independent of protein con-
centration. The running times were ≥ 70 and ≥ 80 min for 
the turoctocog alfa product reconstituted in 4.3- and 1.0-
ml 0.9% sodium chloride, respectively. HMWP content 
was determined by calculating the area percentage of the 
HMWP peak on the resulting chromatogram. The accept-
ance criterion was ≤ 3.9% HMWP.
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2.3.5  Water Content
The water content of turoctocog alfa dry product samples 
prior to reconstitution was evaluated by near-infrared 
(NIR) spectroscopy using an FT-NIR Spectrometer (MPA, 
Bruker, Billerica, MA, USA) equipped with an integrat-
ing sphere (or equivalent). Turoctocog alfa samples were 
scanned in the frequency ranges of 7502.1–6098.1 and 
5450.1–4597.7 nm at a resolution of 8 cm−1, and an aver-
age of 32 scans was recorded for each spectrum. The spec-
trometer was equipped with OPUS software (Bruker) (or 
equivalent), and data were analyzed using a partial least 
squares fit method. Turoctocog alfa samples were analyzed 
without any pretreatment; however, NIR spectra data were 
pretreated using vector normalization and a first derivative 
to enhance spectral information and correct interferences 
from the analyzed material that might otherwise induce 
baseline drift and changes in maximum absorbance [18]. 
Karl-Fischer coulometry was used as the reference method 
for determining the calibration function and to analyze 
samples in cases where NIR spectroscopy results were not 
accepted (for example, because of persistent outliers) [19]. 
The acceptance criterion for water content was ≤ 1.7%.
3  Results
3.1  Potency
The potency of turoctocog alfa test samples was not 
affected during 10 cycles of temperature changes between 
5 °C AH and 40 °C/75% RH (Fig. 2a). Similarly, there 
were no changes in the potency following subsequent 
storage at 40 °C/75% RH for 3 months and 5 °C AH for 
1 month (Fig. 2b). Potency results for test samples were 
comparable to those of reference samples, and all results 
were within shelf-life specifications.
3.2  Purity
Repeated temperature cycling resulted in a slight reduc-
tion in product purity compared with the reference sam-
ples. The purity of the 250-IU sample had greater variabil-
ity than the 1500- and 3000-IU products; this is because 
the total amount of turoctocog alfa per vial in the 250-IU 
sample was very low (Fig. 3a). Purity decreased slightly 
in all product strengths throughout subsequent storage at 
40°/75% RH for 3 months. During the final month of storage 
at 5 °C, no further decreases in purity were observed for the 
turoctocog alfa 1500- and 3000-IU products. There was an 
additional reduction in purity in the turoctocog alfa 250-IU 
sample (Fig. 3b), which had lower purity levels than the 
corresponding reference sample, whereas the purity for all 
1500- and 3000-IU test samples was similar to that of the 
reference samples. All purity levels were maintained within 
shelf-life specification limits.
3.3  Oxidized Forms
There was a slight increase in oxidized forms during tem-
perature cycling for all strengths of turoctocog alfa tested 
(Fig. 4a). This increase continued for all strengths during 
subsequent storage at 40 °C/75% RH for 3 months, although 
no further change was observed after the final month of stor-
age at 5 °C for 1 month for the 250- and 1500-IU samples, 
whereas the level of oxidized forms decreased slightly for 
the turoctocog alfa 3000-IU sample (Fig. 4b). All results 
were maintained within shelf-life specification limits.
3.4  High Molecular Weight Protein
HMWP levels in the turoctocog alfa test samples varied fol-
lowing multiple temperature changes. There was a slight 
overall increase for the 250- and 1500-IU samples, although 
the variation in HMWP levels was greatest for the 250-IU 
samples (Fig. 5a). There was also a slight increase in HMWP 
levels during subsequent storage at 40 °C (3 months) and 
5 °C (1 month) (Fig. 5b). However, at all times and for all 
strengths, results obtained for the test samples were within 
shelf-life specifications and comparable with those from 
reference samples.
3.5  Water Content
At study start, the turoctocog alfa dry powdered products 
had low water content (data not shown). Small increases 
in water content were observed during the temperature-
cycling phase and subsequent storage at 40 °C/75% RH 
for 3 months for all product strengths. The water content 
for each of the three turoctocog alfa doses prior to the 
first temperature cycle, at the end of the tenth temperature 
cycle, and at the end of 3 months’ storage at 40 °C were 
0.5%, 0.7%, and 1.3% (250 IU); 0.4%, 0.7%, and 1.3% 
(1500 IU); and 0.3%, 0.6%, and 1.0% (3000 IU), respec-
tively. There were no further changes in water content 
for the 250- and 3000-IU samples during storage at 5 °C 
for 1 month; however, water content decreased slightly 
to 1.1% for the intermediate strength sample (1500 IU). 
Water content levels were comparable between reference 
and test samples, and all results remained within shelf-life 
specification limits.
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Fig. 2  Potency of turoctocog alfa. Potency of product strengths 250, 
1500, and 3000 IU assessed during a 10 temperature cycles between 
5 °C/AH and 40 °C/75% RH*; b storage at 40 °C for 3 months, fol-
lowed by storage at 5 °C for 1 month†. *During temperature cycling, 
turoctocog alfa test samples were evaluated for potency at seven time 
points (0, 3, 17, 31, 45, 59, and 66 days), whereas reference samples 
were assessed at three time points (0, 31, and 66 days). †Month 0 is 
the end of the temperature-cycling stage; months 1–3 show storage 
at 40 °C; month 4 shows storage at 5 °C. AH ambient humidity, ref 
reference sample, RH relative humidity
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4  Discussion
This study examined the stability of turoctocog alfa in 
response to repeated temperature changes, after sub-
sequent storage at 40 °C/75% RH for 3 months and at 
5 °C for 1 month following an extended storage period 
of 24 months at 5 °C. The temperature-cycling phase of 
this study replicates a situation common to many patients 
where their product is removed and then returned, unused, 
to a refrigerator multiple times. While many FVIII prod-
ucts are stable at ambient temperatures up to 30 °C for a 
limited time [15, 16, 20–22], for patients living in and/
or traveling to a region where daytime temperatures can 
exceed 30 °C, their product may be exposed to fluctuating 
Fig. 3  Purity of turoctocog alfa. Purity of product strengths 250, 
1500, and 3000 IU assessed during a 10 temperature cycles between 
5 °C/AH and 40 °C/75% RH*; b storage at 40 °C for 3 months fol-
lowed by storage at 5 °C for 1 month†. *During temperature cycling, 
turoctocog alfa test samples were evaluated for purity at all 11 time 
points (0, 3, 10, 17, 24, 31, 38, 45, 52, 59, and 66  days), whereas 
reference samples were assessed at three time points (0, 31, and 
66  days). †Month 0 is the end of the temperature-cycling stage; 
months 1–3 show storage at 40 °C; month 4 shows storage at 5 °C. 
AH ambient humidity, ref reference sample, RH relative humidity
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Fig. 4  Oxidized forms. Turoctocog alfa product strengths 250, 1500, 
and 3000 IU assessed during a 10 temperature cycles between 5 °C/
AH and 40 °C/75% RH*; b storage at 40 °C for 3 months followed 
by storage at 5  °C for 1  month†. *During temperature cycling, 
turoctocog alfa test samples were evaluated for oxidized forms at 
all 11 time points (0, 3, 10, 17, 24, 31, 38, 45, 52, 59, and 66 days), 
whereas reference samples were assessed at three time points (0, 31, 
and 66 days). †Month 0 is the end of the temperature-cycling stage; 
months 1–3 show storage at 40 °C; month 4 shows storage at 5 °C. 
AH ambient humidity, ref reference sample, RH relative humidity
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Fig. 5  HMWP content. Turoctocog alfa product strengths 250, 1500, 
and 3000 IU assessed during a 10 temperature cycles between 5 °C/
AH and 40 °C/75% RH*; b storage at 40 °C for 3 months followed by 
storage at 5 °C for 1 month†. *During temperature cycling, turocto-
cog alfa test samples were evaluated for HMWP at all 11 time points 
(0, 3, 10, 17, 24, 31, 38, 45, 52, 59, and 66 days), whereas reference 
samples were assessed at three time points (0, 31, and 66  days). 
†Month 0 is the end of the temperature-cycling stage; months 1–3 
show storage at 40 °C; month 4 shows storage at 5 °C. AH ambient 
humidity, HMWP high molecular weight protein, ref reference sam-
ple, RH relative humidity
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temperature conditions, particularly as patients may want 
to store their product in a refrigerator or transport it in a 
cooler after exposure to higher room temperatures.
Our study showed that turoctocog alfa remained stable 
when subjected to temperature cycling (10 cycles between 
5 °C and 40 °C) over a 2-month period. There were no unex-
pected changes, and the results remained within shelf-life 
specification limits, for the parameters of potency, purity, 
HMWP, oxidized forms, and water content across the range 
of turoctocog alfa strengths tested (250, 1500, and 3000 IU). 
The consistency in purity and potency of turoctocog alfa 
during this period of temperature cycling is important for 
patients for whom storage flexibility is key. Furthermore, 
all stability parameters remained within shelf-life specifica-
tion limits after the temperature cycles and subsequent stor-
age at 40 °C/75% RH for 3 months. It is worth mentioning 
that, during this study, the stability of the drug products was 
assessed toward the end of the product’s shelf-life, when the 
product may be most susceptible to degradation.
Turoctocog alfa has a robust and reliable manufactur-
ing process, resulting in a product with high purity and 
homogeneity [23, 24]. This purification process may be 
important for the observed stability of turoctocog alfa 
when stored at high temperatures and variable conditions. 
Increased understanding of patient/caregiver perspectives 
and preferences in terms of hemophilia treatment is lead-
ing to a growing awareness that factors such as product 
storage, portability, and usage are directly related to suc-
cessful disease management [3]. Indeed, a wide range of 
temperature storage conditions has been cited as one of 
the biggest drivers of product choice among adult patients 
and a significant factor in patient satisfaction [4]. Fur-
thermore, flexible factor storage conditions may reduce 
wastage caused by improper storage [3]. Although many 
patients desire factor products with flexible storage condi-
tions, many are unaware that some products already offer 
such benefits [4]. It is therefore important that hemophilia 
physicians and nurses provide education in this area.
A limitation of our study is that, while a range of drug 
strengths were assessed, only one batch number per drug 
strength was used in each assay. However, there was no sig-
nificant impairment of any stability parameter evaluated for 
any of the three doses tested. Although not a limitation to 
this study and FVIII product alone, it should be noted that, 
because of insufficient space to write notes on individual 
turoctocog alfa product labels or packaging, it is difficult 
to track when a vial is moved in and out of the refrigerator. 
Therefore, the results of this study provide more reassur-
ance about the storage flexibility of turoctocog alfa than an 
indication of the exact number of times turoctocog alfa can 
be cycled between these temperatures.
5  Conclusions
From these results, we conclude that turoctocog alfa can 
be subjected to variations in storage conditions, including 
cycling between temperatures of 5 °C and ≤ 40 °C (simu-
lating removal and replacement into a refrigerator) over a 
2-month period and subsequent storage for an additional 
3 months up to 40 °C without loss of stability. These findings 
should reassure healthcare providers and patients/caregivers 
that turoctocog alfa can be stored under flexible conditions 
in everyday practice, which should also lead to a potential 
reduction in wastage and increased patient satisfaction.
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